PROGRAM & SCHEDULE OF EVENTS ISPOR 17th Annual European Congress 8-12 NOVEMbER 2014

Transcription

ISPOR 17th Annual European Congress
8-12 November 2014
Amsterdam, The Netherlands
PROGRAM &
SCHEDULE OF EVENTS
8-12 November 2014, Amsterdam RAI, Amsterdam, The Netherlands
program & schedule of events
SATURDAY, 8 NOVEMBER
9:00-18:00
PRE-CONGRESS SHORT COURSES Short Course Registration Required
Lunch – Attendees on their own
18:30-19:30 EDUCATIONAL SYMPOSIUM Room: Forum (Ground Floor)
A DEBATE ON EVIDENCE SOURCES TO SUPPORT COVERAGE AND REIMBURSEMENT
Sponsored by ICON Commercialisation & Outcomes
Sunday, 9 November
8:00-17:00
PRE-CONGRESS SHORT COURSES Short Course Registration Required
Lunch – Attendees on their own
ALTERNATIVE AND EARLY ACCESS SCHEMES: SHORT-TERM GAINS AND LONG-TERM SUSTAINABILITY
Sponsored by CBPartners
REAL-WORLD EFFECTIVENESS STUDIES: WHY NOW & NOW WHAT?
Sponsored by LASER ANALYTICA
Monday, 10 November
7:30-8:30
EDUCATIONAL SYMPOSIUM Room: Elicium 1 (1st Floor)
VALUE EVIDENCE REQUIREMENTS AND ACCESS PROCEDURES FOR ORPHAN DRUGS IN EUROPE
Sponsored by Xcenda
8:45-14:15
RESEARCH POSTER PRESENTATIONS - SESSION I Room: Hall 2-3 (Ground Floor)
8:45-10:45
WELCOME & FIRST PLENARY SESSION Room: Auditorium (Ground Floor) [Overflow Room: G104-105 (1st Fl)]
WELCOME
Adrian Towse, MA, MPhil, 2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
Towse
CONGRESS PROGRAM OVERVIEW
Carin A. Uyl-de Groot, PhD, Program Committee Co-Chair, Professor of Health Technology Assessment, Head of Health Economics & Director,
Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (iMTA/iBMG), Erasmus University Rotterdam,
Rotterdam, The Netherlands
Finn Børlum Kristensen, MD, PhD, Program Committee Co-Chair, Professor, Health Services Research & Health Technology Assessment,
University of Southern Denmark, and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
Uyl-de Groot Kristensen
ISPOR 2014 AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARD
Presented by: Mark J. Sculpher, MSc, PhD, Chair, ISPOR Avedis Donabedian Lifetime Achievement Award in Health Outcomes Committee and Professor of
Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
AWARDEE: Bengt Jönsson, PhD, Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden
Jönsson
FIRST PLENARY SESSION: CREATING SUSTAINABLE HEALTH SYSTEMS IN EUROPE
Slow economic growth and high public debt levels have put pressure on all European Union (EU) health systems, with a number of them subject to “Troika”
demands for structural reform and substantial cost savings. This is before account is taken of changing demographics; the increase in underlying demands
for health and social care; and income disparities between Member States. During this session, moving to health systems across Europe in which health care
delivery is both affordable and the highest possible quality will be addressed.
Uyl-de Groot
program & schedule of events: Monday, 10 November continued
Moderator: Carin A. Uyl-de Groot, PhD, Professor of Health Technology Assessment, Head of Health Economics & Director, Institute for Medical Technology Assessment/
Institute of Health Care Policy and Management (iMTA/iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands
DELIVERING AFFORDABLE CANCER CARE
Speaker: Richard Sullivan, MD, PhD, Director, Kings Health Partners Institute of Cancer Policy & Global Health, London, UK
HEALTH CARE REFORM IN EUROPE: MOVING TOWARDS INTEGRATED CARE AND MATCHING PERFORMANCE-BASED PAYMENT
SYSTEMS
Speaker: Maureen P. M. H. Rutten-van Mölken, PhD, MSc, Professor of Economic Evaluations of Innovative Health Care for Chronic
Diseases, Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (iMTA/iBMG), Erasmus University
Rotterdam, Rotterdam, The Netherlands
DIFFERENTIAL PRICING ACROSS EUROPE – ADDRESSING CENTRAL AND EASTERN EUROPEAN COUNTRY NEEDS
Speaker: Zoltán Kaló, MSc, MD, PhD, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd
University (ELTE) and Founder & Chief Executive Officer, Syreon Research Institute, Budapest, Hungary
Respondent: Lieven Annemans, PhD, MMan, MSc, Professor of Health Economics, Ghent University, Gent, Belgium
Sullivan
Mölken
Kaló
Annemans
10:45-11:00 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I Room: Hall 2-3 (Ground Floor)
Coffee sponsored by Optum
Cookies sponsored by Alliance Life Sciences
11:00-12:00 ISSUE PANELS - SESSION I
HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES
IP1: HOW CAN HTA BENEFIT FROM INCREASED DATA TRANSPARENCY? Room: Elicium 1 (1st Floor)
Moderator: Meindert Boysen, MSc, HPPF, Director, Technology Appraisal Programme, Centre for Health Technology Evaluation, National Institute for Health and Care
Excellence (NICE), Manchester, UK
Panelists: Lesley Stewart, PhD, Director, Centre for Reviews and Dissemination, University of York, Heslington, York, UK; Beth S Woods, MSc, Research Fellow, Centre
for Health Economics, University of York, Heslington, York, UK; Jens Grueger, PhD, Vice President, Head of Global Health Economics & Pricing, Global Health Economics &
Pricing, F. Hoffmann-La Roche, Basel, Switzerland
IP2: SUCCESS CRITERIA OF GENERIC AND BIOSIMILAR DRUG POLICIES: NOT AS EASY AS IT LOOKS Room: G104-105 (1st Floor)
Moderator: Anke-Peggy Holtorf, PhD, MBA, Managing Director, Health Outcomes Strategies, Basel, Switzerland
Panelists: Tomas Tesar, PharmD, PhD, MBA, Member, Reimbursement Committee of the Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak
Republic; Nick Haggar, MBA, Head, Western Europe, Middle East and Africa and President, European Generic Medicines Association (EGA), Brussels, Belgium; Zoltán Kaló,
MD, MSc, PhD, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary
USE OF REAL WORLD DATA ISSUES
IP3: HOW DESIRABLE, FEASIBLE, AND ACCEPTABLE IS THE INCLUSION OF REAL-WORLD EVIDENCE IN HTA DECISION MAKING ACROSS EUROPE?
Room: Elicium 2 (1st Floor)
Moderator: Sarah Garner, PhD, Associate Director for Research and Development, National Institute for Health and Care Excellence (NICE), London, UK
Panelists: Alexandre Joyeux, PhD, Director, Global Patient Access, Novartis Pharma AG, Basel, UK; Keith R Abrams, PhD, Professor of Medical Statistics & Head of
Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK; Wim Goettsch, PhD, Advisor, International Affairs and Academia,
National Health Care Institute (ZIN) and EUnetHTA Partner, Diemen, The Netherlands
CLINICAL OUTCOMES RESEARCH ISSUES
IP4: SHOULD WE ADJUST OVERALL SURVIVAL ESTIMATES FOR TREATMENT SWITCHING IN ONCOLOGY? Room: G102-103 (1st Floor)
Moderator: Anke van Engen, MSc, Senior Director, Quintiles Consulting, Hoofddorp, The Netherlands
Panelists: Nicholas R Latimer, PhD, Professor of Health Economics, ScHARR, Health Economics and Decision Science, University of Sheffield, Sheffield, UK; YvonneBeatrice Böhler, MD, MBA, Professor for Pharmamanagement, Faculty of Applied Natural Sciences, Cologne University of Applied Sciences, Leverkusen, Germany; Stefan
Holmstrom, MSc, Director, HEOR, Astellas Pharma Global Development, Leiden, The Netherlands
ECONOMIC OUTCOMES RESEARCH ISSUES
IP5: IT’S NOT SO LONELY ANYMORE: HOW ARE HEALTH SYSTEM PLAYERS ADAPTING VALUE DEMONSTRATION AND ACCESS PATHWAYS TO ADDRESS AN
INCREASINGLY CROWDED ORPHAN AND NICHE PRODUCT AREA IN ORDER TO OPTIMIZE PUBLIC HEALTH? Room: G106-107 (1st Floor)
Moderator: John J Doyle, DrPH, Managing Director & Practice Leader, Managed Markets, US, Market Access, Quintiles, Hawthorne, NY, USA
Panelists: Josie Godfrey, MAs, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK; Donald
Han, BA, Vice President, Payer Insights & Access Regional Lead, Pfizer, Collegeville, PA, USA; Eric C Faulkner, MPH, Practice Leader, Global Market Access, Quintiles,
Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians, and Assistant Professor, Institute for
Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
12:00-14:15 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I Room: Hall 2-3 (Ground Floor)
Lunch sponsored by BaseCase
12:15-13:15 EDUCATIONAL SYMPOSIUM Room: Auditorium (Ground Floor)
BIG DATA, ADVANCED ANALYTICS, AND THE TRANSFORMATION OF HEALTH CARE DELIVERY: PRACTICAL APPLICATIONS
IN HEALTH CARE RESEARCH
Sponsored by IMS Health
12:15-13:15 STUDENT RESEARCH SHOWCASE Room: G104-105 (1st Floor)
OUTCOMES RESEARCH HAVING A HIGH IMPACT ON NEW CHALLENGES FOR IMPROVING EUROPEAN HEALTH CARE
This session will feature four outcomes research studies, conducted by ISPOR student members and presented at the ISPOR 17th Annual European Congress. Each student
author will present a brief summary of their research study, conclusions and will then discuss how their research will have a high impact on new challenges for improving
European health care.
Moderators: Dennis Raisch PhD, Professor, University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; Zeba M. Khan PhD, RPh, Vice President, Strategic
Market Access & Policy, Celgene Corporation, Summit, NJ, USA,
Speakers: Jane Yc Chan, MA, Msc, London School of Economics, London, UK; Henk Broekhuizen, MSc, University of Twente; Enschede, The Netherlands; Carina Schey,
PharmD, GMAS University of Groningen, St-Prex, Switzerland; Frank Moriarty, BSc (Pharm), MPharm, Royal College of Surgeons in Ireland, Dublin, Ireland
13:15-14:15 POSTER AUTHOR DISCUSSION HOUR - SESSION I Room: Hall 2-3 (Ground Floor)
14:15-15:15 RESEARCH PODIUM PRESENTATIONS - SESSION I
(Page numbers refer to Podium Abstracts in Value in Health 17(7))
CANCER OUTCOMES RESEARCH STUDIES Room: Auditorium (Ground Floor)
Moderator: Ursula Rochau, MSc, Senior Scientist, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health and
Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, and Division of Health Technology Assessment and Bioinformatics,
Oncotyrol - Center for Personalized Cancer Medicine, Hall i.T., Austria
pgA323 CN1 LONG-TERM IMPACT OF THE DUTCH COLORECTAL CANCER SCREENING PROGRAMME ON CANCER INCIDENCE: EXPLORATION OF THE
14:15-14:30 SERRATED PATHWAY Greuter MJ1, Lew J2, Berkhof J1, Canfell K2, Dekker E3, Meijer GA1, Coupe VM1, 1VU University Medical Center, Amsterdam, The Netherlands, 2University of
New South Wales, Sydney, Australia, 3Academic Medical Center, Amsterdam, The Netherlands
pgA323 CN2 PRIMARY TREATMENTS FOR INTERMEDIATE-RISK PROSTATE CANCER: A COST-EFFECTIVENESS AND VALUE-OF-INFORMATION ANALYSIS
14:30-14:45 Piena M1, IJzerman MJ2, Steuten LM3, 1PANAXEA bv, Enschede, The Netherlands, 2University of Twente and MIRA institute for Biomedical Technology &
Technical Medicine, Enschede, The Netherlands, 3University of Twente, Enschede, The Netherlands
pgA323 CN3 EARLY STAGE COST-EFFECTIVENESS ANALYSIS OF A BRCA1-LIKE TEST TO DETECT TRIPLE NEGATIVE BREAST CANCERS RESPONSIVE TO HIGH
14:45-15:00 DOSE ALKYLATING CHEMOTHERAPY
Miquel Cases A1, Steuten LM2, Retèl VP1, van Harten WH2, 1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Twente, Enschede,
The Netherlands
pgA323 CN4 THE COST OF COSTING TREATMENTS INCORRECTLY: ERRORS IN THE APPLICATION OF DRUG PRICES IN ECONOMIC MODELS DUE TO DIFFERING
15:00-15:15 PATIENT WEIGHTS
Hatswell AJ1, Porter J1, Hertel N2, Lee D1, 1BresMed, Sheffield, UK, 2Bristol Myers Squibb, Uxbridge, UK
CONCEPTUAL PAPERS Room: G104-105 (1st Floor)
Moderator: James D. Chambers, PhD, MPharm, MSc, Assistant Professor, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and
Health Policy Studies, Tufts Medical Center, Boston, MA, USA
pgA324 CP1 THE EVALUATION OF ECONOMIC METHODS TO ASSESS THE SOCIAL VALUE OF MEDICAL INTERVENTIONS FOR ULTRA-RARE DISORDERS (URDS)
14:15-14:30 Schlander M1, Garattini S2, Holm S3, Kolominsky-Rabas PL4, Nord E5, Persson U6, Postma MJ7, Richardson J8, Simoens S9, de Sola-Morales O10, Tolley
K11, Toumi M12, 1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological
Research, Milano, Italy, 3University of Manchester, Manchester, UK, 4University of Erlangen, Erlangen, Germany, 5Norwegian Institute of Public Health,
Oslo, Norway, 6The Swedish Institute for Health Economics (IHE), Lund, Sweden, 7University of Groningen, Groningen, The Netherlands, 8Monash
University, Clayton, Victoria, Australia, 9KU Leuven, Leuven, Belgium, 10Sabirmedical, Barcelona, Spain, 11Tolley Health Economics Ltd., Buxton, Derbyshire,
UK, 12University Claude Bernard Lyon 1, Lyon, France
pgA324 CP2 VALUE IN THE MAKING: HARVESTING THE VALUE OF COMPLEX MEDICAL INNOVATIONS IN PRACTICE
14:30-14:45
Abrishami P1, Boer A2, Horstman K1, 1Maastricht University, Maastricht, The Netherlands, 2National Health Care Institute, Diemen, The Netherlands
pgA324 CP3 EVALUATING THE QUALITY OF EVIDENCE FROM A NETWORK META-ANALYSIS
14:45-15:00 Higgins JP1, Del Giovane C2, Chaimani A3, Caldwell DM1, Salanti G3, 1University of Bristol, Bristol, UK, 2University of Modena and Reggio Emilia, Modena,
Italy, 3University of Ioannina School of Medicine, Ioannina, Greece
pgA324 CP4 AMENDING THE GUIDE TO METHODS OF TECHNOLOGY APPRAISAL AT NICE TO INCORPORATE TWO NEW VALUE ELEMENTS: BURDEN OF
15:00-15:15 ILLNESS AND WIDER SOCIETAL IMPACT
Knight H1, Boysen M1, Stevens A2, Longson C1, 1National Institute for Health and Care Excellence, Manchester, UK, 2University of Birmingham, Birmingham, UK
DIAGNOSTIC RESEARCH STUDIES Room: G106-107 (1st Floor)
Moderator: Laura T. Burgers, MSc, Researcher, Institute for Medical Technology Assessment/Institute of Health Care Policy and Management, Erasmus University
Rotterdam, Rotterdam, The Netherlands
pgA324 DI1 COST-EFFECTIVENESS (CE) OF IMAGING-GUIDED STRATEGIES FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE (CAD): RESULTS FROM THE
14:15-14:30 EVINCI STUDY
Lorenzoni V1, Pierotti F1, Bellelli S1, Neglia D2, Rovai D2, Turchetti G1, 1Scuola Superiore Sant’Anna, Pisa, Italy, 2National Research Council, Pisa, Italy
pgA324 DI2 THE VALUE OF RISK-STRATIFIED INFORMATION IN THE NATIONAL LUNG CANCER SCREENING TRIAL
14:30-14:45 Soeteman DI1, Cohen JT1, Neumann PJ2, Wong JB1, Kent DM1, 1Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA, 2Tufts Medical
Center, Boston, MA, USA
pgA325 DI3 EFFECT OF SELF-MONITORING OF BLOOD GLUCOSE ON GLYCEMIC CONTROL, CLINICAL OUTCOMES, AND HEALTH CARE COSTS IN DIABETIC
14:45-15:00 PATIENTS USING INSULIN: A RETROSPECTIVE ANALYSIS
Degli Esposti L, Saragoni S, Blini V, Buda S, CliCon Srl, Ravenna, Italy
pgA325 DI4 DIAGNOSING ANXIETY DISORDERS IN PRIMARY CARE: A SYSTEMATIC REVIEW AND META-ANALYSIS
15:00-15:15 Olariu E1, Rodrigo M2, Alvarez Lopez P3, Castro-Rodriguez J3, Martin-Lopez LM3, Alonso J4, Garcia Forero C1, 1PRBB - IMIM Instituto Hospital del Mar de
Investigaciones Médicas, Barcelona, Spain, 2Pompeu Fabra University, Barcelona, Spain, 3Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain, 4IMIMResearch Institute Hospital del Mar, Barcelona, Spain
HEALTH CARE EXPENDITURE STUDIES Room: Elicium 1 (1st Floor)
Moderator: Evelyn Walter, PhD, Managing Director, Institute for Pharmacoeconomic Research, Vienna, Austria
pgA325 HC1 DETERMINANTS OF INCREASING THE LIKELIHOOD FOR A POSITIVE DRUG REIMBURSEMENT RECOMMENDATION IN SCOTLAND
14:15-14:30
Pantiri K, Baeten S, Majer IM, Heeg B, Charokopou M, Pharmerit International, Rotterdam, The Netherlands
pgA325 HC2 BIOSIMILARS VERSUS BRANDS FOR RHEUMATOID ARTHRITIS: EU5 PAYERS AND PRESCRIBERS PLACE THEIR BETS
14:30-14:45
Cox J1, Fletcher-Louis M1, Kang B2, 1Decision Resources Group, London, UK, 2Decision Resources Group, Burlington, MA, USA
pgA325 HC3 PREFERENCES FOR PRIORITIZING PATIENTS WITH RARE DISEASES: A SURVEY OF THE GENERAL POPULATION IN SWEDEN
14:45-15:00
Wiss J, Levin L, Linköping University, Linköping, Sweden
pgA326 HC4 UNDERSTANDING THE PAYER DILEMMA WITH BIOSIMILAR MABS: STRIKING THE RIGHT BALANCE BETWEEN BUDGET NEEDS AND PATIENT
15:00-15:15 OUTCOMES
Vidal Pinheiro A, Ziai Buetas A, Storer M, ICON, London, UK
RESEARCH ON METHODS - MODELING STUDIES Room: Elicium 2 (1st Floor)
Moderator: Phil McEwan, PhD, Director, Health Economics and Outcomes Research Ltd., Monmouth, Wales, UK
pgA326 MO1 QUASI-MONTE CARLO SIMULATION AND VARIANCE REDUCTION TECHNIQUES SUBSTANTIALLY REDUCE COMPUTATIONAL REQUIREMENTS OF
14:15-14:30 PATIENT-LEVEL SIMULATION MODELS: AN APPLICATION TO A DISCRETE EVENT SIMULATION MODEL
Treur M1, Postma M2, 1Pharmerit International, Rotterdam, The Netherlands, 2University of Groningen, Groningen, The Netherlands
pgA326 MO2 TRANSITION PROBABILITY ESTIMATION USING REPEATED SAMPLING FROM A FITTED MIXED MODEL
14:30-14:45 Gupta S1, Bhattacharyya S1, Sonathi V1, Bakuli A1, Mathur AK1, Leteneux C2, 1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharma AG, Basel,
Switzerland
pgA326 MO3 EXTRAPOLATION OF TRIAL-BASED SURVIVAL CURVES USING EXTERNAL INFORMATION
14:45-15:00 Guyot P1, Welton NJ2, Beasley M3, Ades A2, 1Mapi, Houten, The Netherlands, 2University of Bristol, Bristol, UK, 3Bristol Haematology and Oncology Centre,
Bristol, UK
pgA326 MO4 ESTIMATING SURVIVAL DATA FROM PUBLISHED KAPLAN-MEIER CURVES: A COMPARISON OF METHODS
15:00-15:15
Perry R1, Taylor M2, Lewis L2, Yellowlees A1, Fleetwood K1, Barata T1, 1Quantics Consulting Ltd., Edinburgh, UK, 2York Health Economics Consortium, York, UK
QALY-RELATED STUDIES Room: G102-103 (1st Floor)
Moderator: Kostas Athanasakis PhD, Research Fellow, National School of Public Health and President of the Hellenic Association of Pharmacoeconomics, Athens, Greece
pgA326 QA1 ECONOMIC ORPHANS? THE PREVALENCE OF CHILD-SPECIFIC UTILITIES IN NICE APPRAISALS FOR PAEDIATRIC INDICATIONS
14:15-14:30
Montgomery S, Hassan M, Kusel J, Costello Medical Consulting Ltd., Cambridge, UK
pgA327 QA2 COST-UTILITY OF CANCER THERAPIES – THE ‘COST’ OF DIFFERENT UTILITY GENERATION STRATEGIES
14:30-14:45 Meads DM1, McCabe C2, Hulme CT1, Edlin R3, Kharroubi SA4, Browne C5, Ford H6, Dunn J7, Marshall A7, 1University of Leeds, Leeds, UK, 2University of
Alberta, Edmonton, AB, Canada, 3University of Auckland, Auckland, New Zealand, 4University of York, York, UK, 5Evidera, London, UK, 6Addenbrooke’s
Hospital, Cambridge, UK, 7University of Warwick, Coventry, UK
pgA327 QA3 DO NEW CANCER DRUGS OFFER GOOD VALUE FOR MONEY? THE PERSPECTIVE OF ONCOLOGISTS, PAYERS, PATIENTS, AND GENERAL POPULATION
14:45-15:00 Dilla T1, Lizán L2, Paz S2, Garrido P3, Avendaño C4, Cruz JJ5, Espinosa J6, Sacristan JA1, 1Lilly S.A., Madrid, Spain, 2Outcomes 10, Castellon, Spain, 3Hospital
Ramon y Cajal, Madrid, Spain, 4Hospital Puerta de Hierro, Madrid, Spain, 5Hospital Clinico Universitario, Salamanca, Spain, 6Hospital La Paz, Madrid, Spain
pgA327 QA4 REIMBURSEMENT DECISIONS FOR PHARMACEUTICALS IN SWEDEN: THE IMPACT OF COST-EFFECTIVENESS AND DISEASE SEVERITY
15:00-15:15
Nilsson FO1, Svensson M2, Arnberg K1, 1Dental and Pharmaceutical Benefits Agency, Stockholm, Sweden, 2Örebro University, Örebro, Sweden
15:15-15:30 BREAK & EXHIBITS VIEWING Room: Hall 2-3 (Ground Floor)
Coffee sponsored by Optum
Cookies sponsored by Alliance Life Sciences
15:30-19:30 RESEARCH POSTER PRESENTATIONS - SESSION II Room: Hall 2-3 (Ground Floor)
15:30-16:30 RESEARCH PODIUM PRESENTATIONS - SESSION II
(Page numbers refer to Podium Abstracts in Value in Health 17(7))
CARDIOVASCULAR DISEASE RESEARCH STUDIES Room: G102-103 (1st Floor)
Moderator: Manolis Karamalis, MSc, Director Reimbursement & Government Affairs, Central Eastern Europe and Central Asia, Medtronic International, Tolochenaz, Switzerland
pgA327 CV1 THE IMPORTANCE OF TREATMENT CLASSIFICATIONS THAT ACCOUNT FOR CONCOMITANT TREATMENTS IN THE CONTEXT OF A NETWORK
15:30-15:45 META-ANALYSIS COMPARING PHARMACOLOGICAL TREATMENTS FOR CHRONIC HEART FAILURE
Burnett H1, Cope S1, Vieira MC2, Sagkriotis A3, Senni M4, Deschaseaux C3, 1Mapi, Toronto, ON, Canada, 2Novartis Pharma, Health Economics and Outcomes
Research, USA, East Hanover, NJ, USA, 3Novartis Pharma AG, Basel, Switzerland, 4Scompenso e Trapianti di Cuore, Bergamo, Italy
pgA327 CV2 WORK PRODUCTIVITY LOSS AND INDIRECT COSTS ASSOCIATED WITH NEW CARDIOVASCULAR EVENTS IN HIGH-RISK PATIENTS WITH
15:45 - 16:00 HYPERLIPIDEMIA - ESTIMATES FROM POPULATION-BASED REGISTER DATA IN SWEDEN
Banefelt J1, Hallberg S1, Fox KM2, Mesterton J1, Paoli CJ3, Johansson G4, Levin L5, Sobocki P6, Gandra SR3, 1Quantify Research, Stockholm, Sweden,
2
Strategic Healthcare Solutions, LLC, Monkton, MD, USA, 3Amgen, Inc., Thousand Oaks, CA, USA, 4Uppsala University, Uppsala, Sweden, 5Linköping
University, Linköping, Sweden, 6IMS Health, Stockholm, Sweden
pgA328 CV3 INCIDENCE DESCRIPTION AND COSTS OF ACUTE HEART FAILURE IN THE NETHERLANDS
16:00-16:15 Stevanovic J1, Denee L2, Koenders JM2, Postma MJ1, 1University of Groningen, Groningen, The Netherlands, 2Novartis Pharma B.V., Arnhem, The
Netherlands
pgA328 CV4 HEALTH UTILITY IN PATIENTS FOLLOWING CARDIOVASCULAR EVENTS
16:15-16:30 Pockett RD1, McEwan P2, Beckham C3, Shutler S4, Martin S5, Yousef Z6, Bakhai A7, 1Swansea University, Cardiff, UK, 2Health Economics and Outcomes
Research Ltd., Cardiff, UK, 3Roche Products Ltd., Welwyn Garden City, UK, 4F. Hoffmann-La Roche Ltd., Basel, Switzerland, 5Peterborough and Stamford
Hospitals NHS Foundation Trust, Peterborough, UK, 6University Hospital of Wales, Cardiff, UK, 7Barnet and Chase Farm Hospitals NHS Trust, Barnet, UK
HEALTH SERVICES RESEARCH STUDIES Room: G104-105 (1st Floor)
Moderator: Imre Boncz, MD, MSc, PhD, Habil, Professor & Vice Dean, Institute for Health Insurance, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
pgA328 HS1 FOLLOW-UP AUTOANTIBODY TESTING AND HEALTH CARE UTILIZATION AMONG PATIENTS WITH (SUSTAINED) CELIAC DISEASE ACTIVITY IN THE
15:30-15:45 NETHERLANDS
Kuiper JG1, Penning-van Beest FJ1, Naessens D2, Leon F3, Herings RM1, 1PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands, 2Janssen
BVBA, Beerse, Belgium, 3Janssen Research & Development, Spring House, PA, USA
pgA328 HS2 THE IMPACT OF DIFFERENT LEVELS OF CLINICAL PHARMACIST INTERVENTIONS ON THE THERAPEUTIC PLAN AND COST SAVING
15:45-16:00
Alkhalaf MS, Dammam Medical Complex, MOH, Dammam, Saudi Arabia
pgA328 HS3 IMPACT OF MORBIDITY IN POPULATIONS OF NORTH LONDON CLINICAL COMMISSIONING GROUPS ON PATIENT ADMISSION RATES AND GP
16:00-16:15 REFERRALS
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J, Costello Medical Consulting Ltd., Cambridge, UK
pgA329 HS4 INFORMATION USED IN THE DECISION-MAKING PROCESS REGARDING INFLUENZA VACCINATION POLICY: PERCEPTIONS OF STAKEHOLDERS IN
16:15-16:30 FRANCE AND THE NETHERLANDS
Silva ML1, Perrier L2, Paget J3, Mosnier A4, Buthion V5, Cohen JM4, Späth H6, 1Research Group in Health Economics (GATE, UMR 5824, CNRS);
University Lyon 2, Ecully, France, 2Cancer Centre Léon Bérard, Lyon, France, 3Netherlands Institute For Health Services Research (NIVEL), Utrecht,
The Netherlands, 4Regional Group for the Surveillance of Influenza - GROG, Open Rome, Paris, France, 5COACTIS EA 4161, University of Lyon, Lyon,
France, 6University Claude Bernard, Lyon 1 EAM 4128, Lyon, France
MEDICATION ADHERENCE STUDIES Room: Elicium 2 (1st Floor)
Moderator: Maarten Treur, MSc, Senior Research Consultant, Pharmerit International, Rotterdam, The Netherlands
pgA329 MA1 COST-EFFECTIVENESS OF REAL-TIME MEDICATION MONITORING IN CHILDREN WITH ASTHMA
15:30-15:45 Goossens LM1, Vasbinder EC2, Van den Bemt PM3, Rutten-van Mölken MP1, 1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Groene Hart
Hospital, Gouda, The Netherlands, 3Erasmus University Medical Center, Rotterdam, The Netherlands
pgA329 MA2 THE BURDEN ASSOCIATED WITH NON-ADHERENCE IN EUROPEAN PATIENTS WITH DEPRESSION
15:45-16:00
Pedersini R, Kuehl M, Kantar Health, Epsom, UK
pgA329 MA3 ASSESSING THE RELATIONSHIP BETWEEN PATIENT COMPLIANCE TO BLOOD GLUCOSE MONITORING AND HEALTH RELATED QUALITY OF LIFE
16:00-16:15
Dierick K1, Mcbride M2, Pike I3, 1GfK Disease Atlas, Brussels, Belgium, 2GfK USA, New York, NY, USA, 3GfK NOP, London, UK
pgA329 MA4 ADHERENCE TO ANTIRETROVIRAL THERAPY (ART) AMONG ADULT HIV POSITIVE PATIENTS IN VOLTA REGIONAL HOSPITAL, GHANA
16:15-16:30
Okotah AN1, Korbuvi J2, 1Volta Regional Health Directorate, Ghana Health Service, Ho, Ghana, 2Volta Regional Hospital, Ho, Ghana
STUDIES ON NICE ASSESSMENTS Room: Auditorium (Ground Floor)
Moderator: Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
pgA329 NI1 EXPLORING THE FLAWS IN CLINICAL DATA THAT LEAD TO REJECTION OF NICE SUBMISSIONS
15:30-15:45
Hendrich J, Griffiths EA, PAREXEL, London, UK
pgA330 NI2 PREDICTING THE IMPACT OF VALUE-BASED ASSESSMENT ON FUTURE NICE APPRAISALS
15:45-16:00
Beale RC, Maruszczak M, Kusel J, Costello Medical Consulting Ltd., Cambridge, UK
pgA330 NI3 NICE’S PROPOSED VALUE-BASED ASSESSMENT OF HEALTH TECHNOLOGIES: CONCERNS OF INCONSISTENT CONSIDERATION OF SOCIAL VALUES
16:00-16:15 Paulden M1, O’Mahony JF2, Culyer AJ3, McCabe C1, 1University of Alberta, Edmonton, AB, Canada, 2Trinity College Dublin, Dublin, Ireland, 3University of
Toronto, Toronto, ON, Canada
pgA330 NI4 DO HEALTH TECHNOLOGY AGENCIES ACCEPT METHODS FOR DEALING WITH TREATMENT SWITCHING?
16:15-16:30
Maervoet J1, Skaltsa K2, Ivanescu C1, Van Engen A1, 1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles Consulting, Barcelona, Spain
RESEARCH ON METHODS - PREFERENCE STUDIES Room: Elicium 1 (1st Floor)
Moderator: Mark J. C. Nuijten, PhD, MD, MBA, Founder, Ars Accessus Medica, Jisp, The Netherlands
pgA330 PR1 SURVIVAL OR MORTALITY: FRAMING OF THE RISK ATTRIBUTE IN A DISCRETE CHOICE EXPERIMENT
15:30-15:45 Veldwijk J1, Essers BA2, Dirksen CD3, Smit H4, Lambooij MS1, de Wit GA1, 1National Institute for Public Health and the Environment, Bilthoven,
The Netherlands, 2Clinical and Medical Technology Assessment, Maastricht University Medical Centre; CAPHRI, Maastricht University, Maastricht,
The Netherlands, 3Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The
Netherlands, 4University Medical Center Utrecht, Utrecht, The Netherlands
pgA330 PR2 MAPPING FROM SF-6D TO EQ-5D: CHANGES IN ESTIMATES BASED ON THE CHOICE OF ALGORITHM
15:45-16:00 Hatswell AJ1, Ito T2, Ganguly R3, Nassens D4, Almond C1, 1BresMed, Sheffield, UK, 2Janssen-Cilag Ltd., High Wycombe, UK, 3Janssen R&D, LLC, Spring House,
PA, USA, 4Janssen BVBA, Beerse, Belgium
pgA331 PR3 INVESTIGATING THE IMPACT OF PERSPECTIVE ON WEIGHTING QALYS: A DISCRETE CHOICE EXPERIMENT
16:00-16:15
Butt T1, Longworth L2, Rubin G1, Orr S1, 1University College London, London, UK, 2Brunel University, Uxbridge, UK
pgA331 PR4 VALUING EQ-5D-5L: DOES THE ORDERING OF THE HEALTH DIMENSIONS IMPACT ON HEALTH STATE VALUATIONS?
16:15-16:30
Mulhern B1, Shah K2, 1University of Sheffield, Sheffield, UK, 2Office of Health Economics, London, UK
QUALITY OF LIFE AND UTILITY STUDIES Room: G106-107 (1st Floor)
Moderator: Adam B. Smith PhD, Project Director, York Health Economics Consortium Ltd., University of York, Heslington, York, UK
pgA331 QL1 ELICITATION OF HEALTH STATE UTILITIES ASSOCIATED WITH VARYING SEVERITIES OF FLARE IN SYSTEMIC LUPUS ERYTHEMATOSUS
15:30-15:45
Hartz S1, Liu-Leage S2, Paget M2, Pollard C3, Cook J3, Enstone A3, 1Lilly Research Centre, Surrey, UK, 2Lilly France, Cedex, France, 3Adelphi Values, Bollington, UK
pgA331 QL2 THE IMPACT OF DISCRIMINATION, VICTIMIZATION AND SOCIAL STANDING ON HEALTH-RELATED QUALITY OF LIFE
15:45-16:00
Samnaliev M, Boston Childrens Hospital, Boston, MA, USA
pgA331 QL3 QUALITY OF LIFE DECREMENTS AFTER STROKE
16:00-16:15 Dewilde S1, Thijs V2, Annemans L3, Peeters A4, Belgian Stroke Council N5, 1SHE, Brussels, Belgium, 2KULeuven, Leuven, Belgium, 3Ghent University &Brussels
University, Ghent, Belgium, 4Cliniques universitaires Saint-Luc, Bruxelles, Belgium, 5Virga Jesseziekenhuis, Hasselt, Belgium
pgA331 QL4
16:15-16:30
DIFFERENCES BETWEEN HYPOTHETICAL AND EXPERIENCE-BASED VALUE SETS FOR EQ-5D: IMPLICATIONS FOR DECISION MAKERS
Aronsson M, Husberg M, Kalkan A, Eckard N, Alwin J, Linköping University, Linköping, Sweden
16:45-17:45 WORKSHOPS - SESSION I
HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCH
W1: DECISION FRAMEWORKS AND THE ECONOMIC EVALUATION OF VACCINES Room: G102-103 (1st Floor)
Discussion Leaders: Richard J Pitman, PhD, Lead Health Economist & Epidemiologist, Health Economics, ICON Clinical Research, Oxford, UK; Maarten J Postma, PhD,
Professor, Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Elisabeth Fenwick, PhD, Director, Health Economics, ICON Clinical Research,
Oxford, UK; Mark Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
W2: HEALTHY DECISIONS: TOWARDS UNCERTAINTY TOLERANCE IN OUTCOMES RESEARCH Room: G104-105 (1st Floor)
Discussion Leaders: Manuela A. Joore, PhD, Researcher, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre,
Maastricht, The Netherlands; Jill Bindels, MSc, Postdoctoral Researcher, Clinical Epidemiology and Medical Technology Assessment, CAPHRI, Maastricht University Medical
Centre, Maastricht University, Maastricht, The Netherlands; Thomas Wilkinson, MSc, Adviser, Health Economics, NICE International, National Institute for Health and Care
Excellence (NICE), London, UK; Wim Goettsch, PhD, Advisor, International Affairs and Academia, National Health Care Institute (ZIN) and EUnetHTA Partner, Diemen, The
Netherlands
USE OF REAL WORLD DATA
W3: GENERATING EVIDENCE FOR PHARMACOEPIDEMIOLOGY, HEALTH OUTCOMES, AND EPIDEMIOLOGY THROUGH DIRECT-TO-SUBJECT STUDY APPROACHES
Discussion Leaders: Florian Eichmann, PhD, Senior Director, Real World Research & Value, Kantar Health, Munich, Germany; Susan Sinclair, PhD, Associate Professor,
Epidemiologist, Clinical Research Program, UNCW College of Health and Human Services, Wilmington, NC, USA; Klaas Heinemann, MD, PhD, MSc, MBA, Managing
Director, ZEG-Berlin, Berlin, Germany; Marco DiBonaventura, PhD, Vice President, Health Outcomes, Health Outcomes Practice, Kantar Health, New York, NY, USA
CLINICAL OUTCOMES RESEARCH
W4: PROGRESSION FREE SURVIVAL VERSUS OVERALL SURVIVAL AS IMPORTANT CLINICAL ENDPOINTS IN CANCER CLINICAL TRIALS: CAN IMPROVED
VALIDATION OF SURROGATE ENDPOINTS IMPROVE THE UTILITY OF TRIAL EVIDENCE? Room: Elicium 2 (1st Floor)
Discussion Leaders: Edward J Mills, PhD, Associate Professor, Stanford University, Stanford, CA, USA; Heiner C. Bucher, MD, Professor, Internal Medicine, Basel Institute
for Clinical Epidemiology & Biostatistics, Basel, Switzerland; Kalpana D’Oca, BSc, HTA & EBM Manager, Merck Sharp and Dohme Ltd., Hoddesdon, UK; Rachid Rafia, MSc,
Research Fellow, Health Economics and Decision Science, University of Sheffield, Sheffield, UK
ECONOMIC OUTCOMES RESEARCH
W5: VALUE-BASED ASSESSMENT FOR NICE: HOW TO DO THE CALCULATIONS Room: Auditorium (Ground Floor)
Discussion Leaders: Jeanette Kusel, MSci, Head of Health Technology Assessment and Health Economics, Costello Medical Consulting Ltd., Cambridge, UK; Meindert
Boysen, MSc, HPPF, Director, Technology Appraisal Programme, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE),
Manchester, UK; Koonal K. Shah, MSc, Senior Economist, Office of Health Economics, London, UK; Anthony J Hatswell, MSc, Principle Consulting Economist, BresMed,
Sheffield, UK
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH
W6: CHOICE DEFINES VALUE: INTERPRETATION OF CRITERIA WEIGHTS IN MULTI-CRITERIA DECISION MAKING (MCDM) Room: G106-107 (1st Floor)
Discussion Leaders: Axel C. Mühlbacher, PhD, MBA, Professor of Health Economics and Health Care Management, Institute Health Economics and Health Care
Management (IGM), Hochschule Neubrandenburg, Neubrandenburg, Germany; Juan Marcos González, PhD, Senior Research Economist, Health Preference Assessment,
RTI Health Solutions, Research Triangle Park, NC, USA; Benjamin M. Craig, PhD, Associate Member, Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL, USA
17:45-19:30 EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II
Room: Hall 2-3 (Ground Floor)
Reception Sponsored by Evidera
18:00-19:00 ISPOR FORUMS - SESSION I
F1: AN INTRODUCTION TO MULTI-CRITERIA DECISION ANALYSIS IN HEALTH CARE DECISION MAKING - EMERGING GOOD PRACTICES
Room: Auditorium (Ground Floor)
Moderator: Maarten J IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical
Technology & Technical Medicine, Enschede, The Netherlands
Speakers: Nancy Devlin, PhD, Research Director, Office of Health Economics, London, UK; Praveen Thokala, PhD, Research Fellow, School of Health and Related
Research, University of Sheffield, Sheffield, UK; Kevin Marsh, PhD, Director, Modelling and Simulation and Senior Research Scientist, Health Economics, Evidera, London, UK
F2: HOW TO USE THE ‘ASSESSING THE EVIDENCE’ ONLINE QUESTIONNAIRES FOR MODELING, INDIRECT TREATMENT, AND OBSERVATIONAL STUDIES
Room: G104-105 (1st Floor)
Speaker: Randa Eldessouki, MBBCh, MSc, MD, (Former) Director, ISPOR Scientific Initiatives, ISPOR and Lecturer, Faculty of Medicine, Fayoum University, Fayoum, Egypt
F3: IMPROVING PATIENT CARE IN EUROPE BY HARMONIZING DIAGNOSTIC HTA: FINDINGS FROM THE HTA DIAGNOSTIC WORKING GROUP
Moderator: Susan Garfield, DrPH, Senior Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA, USA
Speakers: Eric C Faulkner, MPH, Practice Leader, Global Market Access, Quintiles, Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National
Association of Managed Care Physicians, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of
North Carolina, Chapel Hill, NC, USA; Anne Postulka, MD, Director, Medical and Economic Value, Cepheid Europe, Maurens-Scopont, France; Karsten Berndt, MSc, Chair of
EDMA HTA Task Force and Senior Project Manager Health Technology Assessment, Roche Diagnostics GmbH, Mannheim, Germany
F4: RARE DISEASE: CHALLENGES IN ASSESSMENT AND APPRAISAL OF DIAGNOSTICS & TREATMENTS Room: Elicium 2 (1st Floor)
Moderator: Chris L. Pashos, PhD, Vice President, Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA
Speakers: Ken Redekop, PhD, Associate Professor, HTA, Erasmus University Rotterdam, Rotterdam, The Netherlands; Mondher Toumi, MD, MSc, PhD, Professor & Chair of
Decision Sciences, Department of Public Health and Market Access, University Claude Bernard Lyon I, Lyon, France; Ruediger Gatermann, MA, MBA, Director, Health Policy
& External Affairs Europe, CSL Behring, Marburg, Germany
F5: CAPACITY BUILDING IN PHARMACOECONOMICS AND HTA IN CENTRAL & EASTERN EUROPE (CEE): OPPORTUNITIES IN EDUCATION AND TRAINING
Moderator: Olha Zaliska, PhD, DSci (Pharm), President, ISPOR Ukraine Chapter and Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Speakers: Rok Hren, PhD, MSc IHP (HE), President, ISPOR Slovenia Chapter and Assistant Professor, University of Ljubljana, Ljubljana, Slovenia; Josip Culig, MD, PhD,
President, ISPOR Croatia Chapter and Professor, Pharmacology & Clinical Pharmacology & Head, Pharmacoepidemiology Department, Public Health Institute Zagreb, Zagreb,
Croatia; Pavel Vorobiev, MD, MSc, PhD, President, ISPOR Russia Chapter and Professor & Head, Department of Hematology & Geriatrics and Faculty for Postgraduate
Medical Education, First Sechenov Moscow State Medical University, Moscow, Russia; Vladimir Zah, Health Economics Consultant & Founder, Zrx Outcomes Research Inc.,
Belgrade, Serbia; Mirela Sima, MD, MSc, Health Economics Specialist, Johnson & Johnson, Bucharest, Romania
F6: STANDARD TREATMENT GUIDELINES (STG’S) AND THE EFFECT OF A LACK OF IMPLEMENTATION Room: G102-103 (1st Floor)
Moderator: Mahmoud Elmahdawy, PharmD, President, ISPOR Egypt Chapter and Head, Hospital Pharmacy Administration, Ministry of Health, Lecturer, Clinical and
Hospital Pharmacy, Misr International University, Cairo, Egypt
Speaker: Shelley McGee, BPharm, BCom, M Health Econ, Health Economist, MRC/Wits Rural Public Health and Health Transitions Unit, Wits University School of
Public Health, Johannesburg, South Africa; Peter Agyei-Baffour, PhD, President, ISPOR Ghana Chapter and Health Economics Lecturer, Community Health Department,
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Ola G. Al Ahdab Albannay, PhD, PGD, RPh, President, ISPOR United Arab Emirates Chapter and
Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates; Anthony Waka Udezi, PhD,
Assistant Dean of Pharmacy & Senior Lecturer, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria; Barbara Castelnuovo, PhD, Director, Longitudinal
Cohorts and Post-Doctoral Researcher, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
18:30-19:30 POSTER AUTHOR DISCUSSION HOUR - SESSION II Room: Hall 2-3 (Ground Floor)
19:30-20:30 STUDENT WELCOME RECEPTION Room: Café Amsterdam (Ground Floor)
All students and faculty are welcome to attend! One of the main goals of the ISPOR Student Reception is to increase the connection among student members and faculty.
The 2013 European Congress was a great start in connecting peers and professionals during the reception. Please join us this year to continue the success and increase your
networking connections!
19:30-21:00
ISPOR CENTRAL & EASTERN EUROPE (CEE) NETWORK RECEPTION Room: Topaz Lounge (1st Floor)
A great opportunity to meet & network with ISPOR colleagues from the CEE region!
All attendees interested in the Network, its operation, activities and current initiatives are welcome to attend. ISPOR CEE Network includes the following ISPOR Regional
Chapters: Belarus Chapter, Bosnia & Herzegovina Chapter, Bulgaria Chapter, Croatia Chapter, Cyprus Chapter, Czech Chapter, Greece Chapter, Hungary Chapter, Poland
Chapter, Republic of Macedonia Chapter, Romania Chapter, Russia Chapter, Russia-Far East Chapter, Russia HTA Chapter, Russia St. Petersburg Chapter, Serbia Chapter,
Slovakia Chapter, Slovenia Chapter, Turkish SCP Chapter, and the Ukraine Chapter. For questions on ISPOR CEE Network and to find how to get involved, please send an
email to: ceenet@ispor.org
Tuesday, 11 November
7:30-8:30
EDUCATIONAL SYMPOSIUM Room: Elicium 1 (1st Floor)
A PRAGMATIC DECISION-MAKING FRAMEWORK FOR REIMBURSEMENT IN CENTRAL & EASTERN EUROPEAN (CEE) COUNTRIES
Sponsored by EFPIA
8:45-13:30
RESEARCH POSTER PRESENTATIONS - SESSION III Room: Hall 2-3 (Ground Floor)
9:00-10:00
WORKSHOPS - SESSION II
W7: FROM EVALUATION TO IMPLEMENTATION: HOW TO ENSURE EFFICIENT INVESTMENT IN IMPLEMENTATION OF COST-EFFECTIVE TECHNOLOGIES IN
CLINICAL PRACTICE Room: G102-103 (1st Floor)
Discussion Leaders: Rita Faria, MSc, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Sophie Whyte, PhD, Research Fellow, HEDS,
ScHARR, University of Sheffield, Sheffield, UK; Ties Hoomans, PhD, Assistant Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam,
The Netherlands; Stephen Palmer, MSc, Professor, University of York, Heslington, York, UK
W8: PATIENT REGISTRIES AS HTA TOOLS IN ECONOMIC OUTCOMES RESEARCH: REQUIREMENTS, BARRIERS, AND THE WAY FORWARD Room: Elicium 2
(1st Floor)
Discussion Leaders: Persephone Doupi, MD, PhD, Senior Researcher, PARENT JA WP6 Leader, Information Department, National Institute for Health and Welfare (THL),
Helsinki, Finland; Wim Goettsch, PhD, Advisor, International Affairs and Academia, National Health Care Institute (ZIN) and EUnetHTA Partner, Diemen, The Netherlands;
Marianne Klemp, PhD, Director, The Norwegian Knowledge Centre for the Health Services (NOKC), Oslo, Norway; Matic Meglic, MD, PhD, MBA, Head of Healthcare
Informatics Center, PARENT JA Coordinator, National Institute of Public Health, Slovenia, Ljubljana, Slovenia
program & schedule of events: TUESDAY, 11 November continued
W9: RISK MODELING AND HETEROGENEITY OF TREATMENT EFFECT Room: G104-105 (1st Floor)
Discussion Leaders: David M Kent, MD, MS, Professor of Medicine, Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health
Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA; Ewout W Steyerberg, PhD, Professor of Medical Decision Making, Department of
Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
W10: MAKING MODELS MORE ACCESSIBLE TO DECISION MAKERS Room: Auditorium (Ground Floor)
Discussion Leaders: Michael Drummond, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Michael Barry, MD, PhD,
National Clinical Lead, HSE Clinical Strategy and Programmes, HSE Medicines Management Programme, Dublin, Ireland; Laurie Fazio, BS, Vice President, Dymaxium, Inc.,
Toronto, ON, Canada; Amy O’Sullivan, PhD, Director, HEOR, Vertex, Boston, MA, USA
W11: THE APPLICATION OF HEALTH ECONOMIC GUIDELINES TO STRATIFIED MEDICINE Room: Elicium 1 (1st Floor)
Discussion Leaders: Mark J. C. Nuijten, PhD, MD, MBA, Founder, Ars Accessus Medica, Jisp, The Netherlands; Maarten J. Postma, Professor, Department of Pharmacy,
Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), University of Groningen, Groningen, The Netherlands; W. Ken Redekop, PhD, Associate Professor, Institute
for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health and HTA,
Harvard University, Senior Scientist & Chair of the Department of Public Health, Medical Decision Making and Health Technology Assessment (HTA), UMIT - University for
Health Sciences, Medical Informatics and Technology, and Director of the Division for Health Technology Assessment and Bioinformatics, ONCOTYROL, Hall i. T, Austria
W12: WHAT DO PEOPLE WANT TO KNOW AND NOT WANT TO KNOW? USING STATED-PREFERENCE METHODS TO EVALUATE NEW DIAGNOSTIC TECHNOLOGIES
Discussion Leaders: F. Reed Johnson, PhD, Senior Research Scholar, Duke Clinical Research Institute, Duke University, Durham, NC, USA; Axel C. Mühlbacher, PhD,
MBA, Professor of Health Economics and Health Care Management, Institute Health Economics and Health Care Management (IGM), Hochschule Neubrandenburg,
Neubrandenburg, Germany; Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community
Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; Franziska Severin, MPH, Research Associate,
Helmholtz Zentrum München, Institute of Health Economics and Health Care Management (IGM), Neuherberg, Germany
10:00-10:15 BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III Room: Hall 2-3
(Ground Floor)
Coffee sponsored by Truven Health Analytics
Cookies sponsored by RTI Health Solutions
10:15-11:15 ISSUE PANELS - SESSION II
IP6: WHAT VALUE DO WE PLACE ON A CURE? VALUE DEMONSTRATION CHALLENGES ASSOCIATED WITH INNOVATOR AND REGENERATIVE THERAPIES IN
EUROPE, NORTH AMERICA, AND ASIA Room: G102-103 (1st Floor)
Moderator: Eric C Faulkner, MPH, Practice Leader, Global Market Access, Quintiles, Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National
Association of Managed Care Physicians, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of
North Carolina, Chapel Hill, NC, USA
Panelists: Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK; Don Husereau, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa
and Senior Scientist, University for Health Sciences, UMIT, Ottawa, ON, Canada; Joshua J. Carlson, PhD, MPH, Consultant, VeriTech Corporation, Mercer Island, WA, USA
IP7: ARE WE MOVING TOWARDS COLLABORATIVE EUROPEAN RAPID RELATIVE EFFECTIVENESS ASSESSMENTS? INSIGHTS GLEANED FROM THE EUNETHTA
JOINT ASSESSMENT OF CANAGLIFLOZIN Room: G104-105 (1st Floor)
Moderator: Diana Simone Warren, MSc, Assistant Project Manager, EUnetHTA WP5 Lead, National Health Care Institute (ZIN), Diemen, The Netherlands
Panelists: François Meyer, MD, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Paris, France; Mirjana Huic, MD, PhD, Assistant Director,
Department for Development, Research and HTA, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia; Adrian D. Griffin, MSc, Vice
President, HTA & Market Access Policy, Johnson & Johnson, Buckinghamshire, UK
IP8: DOES THE DATA SPEAK FOR ITSELF? A LOOK AT ADEQUATE DATA GENERATION TO MEET THE DIFFERING REQUIREMENTS OF MULTIPLE HTA AND
REIMBURSEMENT BODIES IN EUROPE Room: Elicium 2 (1st Floor)
Moderator: Timothy R Auton, MSc, PhD, Director, Astellas, Leiden, The Netherlands
Panelists: Omar Dabbous, MD, MPH, Head of Quantitative Sciences, Payer Evidence Group, GlaxoSmithKline, King of Prussia, PA, USA; Friedhelm Leverkus, MS, Director,
HTA&OR, Pfizer Deutschland GmbH, Berlin, Germany; Mira Pavlovic, DrPH, Director, Health Technology Division (DEMESP), Haute Autorité de Santé (HAS), Paris, France
IP9: DOES BURDEN OF DISEASE FIT INTO OUR APPROACHES TO ASSESSMENT AND APPRAISAL? Room: Elicium 1 (1st Floor)
Moderator: Sylvia Vijgen, PhD, Advisor, National Health Care Institute (ZIN), Diemen, The Netherlands
Panelists: Elly Stolk, PhD, Assistant Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands; Morten Aaserud, PhD, Health Economist, NOMA, Oslo,
Norway; Gert Jan van der Wilt, PhD, Professor of Health Technology Assessment, Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The
Netherlands
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP10: HYPOTHETICAL VERSUS EXPERIENCE-BASED EQ-5D VALUATIONS: WHAT ARE THE IMPLICATIONS FOR HEALTH ECONOMIC EVALUATIONS?
Moderator: Ulf Persson, PhD, Chief Executive Officer, The Swedish Institute for Health Economics (IHE), Lund, Sweden
Panelists: Gisela Kobelt, PhD, MS, MBA, President, European Health Economics, Mulhouse, France; Johanna Svensson, MSc, Research Manager, The Swedish Institute for
Health Economics (IHE), Lund, Sweden; Lars-Åke Levin, PhD, Professor, Department of Medical and Health Sciences, IMH, Linköping University, Linköping, Sweden
11:15-13:30 LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III Room: Hall 2-3 (Ground Floor)
11:30-12:30 EDUCATIONAL SYMPOSIUM Room: Auditorium (Ground Floor)
END OF LIFE OR END OF THE ROAD: ARE RISING CANCER COSTS SUSTAINABLE?
Sponsored by Optum
12:15-13:15 ISPOR Medical Devices & Diagnostics Special Interest Group MEETING Open to all Attendees
Room G102-103 (1st Floor)
All ISPOR members interested or working in the area of medical devices and diagnostics are welcome to attend the ISPOR Medical Devices and Diagnostic Special Interest
Group meeting. This meeting will provide an opportunity for participants to discuss issues and challenges within this field and develop projects to address them.
12:30-13:30 POSTER AUTHOR DISCUSSION HOUR - SESSION III Room: Hall 2-3 (Ground Floor)
13:30-15:00 WELCOME & SECOND PLENARY SESSION Room: Auditorium (Ground Floor) [Overflow Room: G104-105 (1st Fl)]
WELCOME
Towse
SECOND PLENARY SESSION: EARLIER ACCESS TO INNOVATION - IS IT WORTH IT?
Patients and manufacturers are keen to see early access for effective new therapies. However, regulators and health technology assessment (HTA) bodies/
payers need enough evidence to be confident that benefit risk and value, respectively, meet their requirements. Proposals for “adaptive licensing” for use by
the European Medicines Agency (EMA) would need to be matched by managed entry arrangements for payers if use was to occur whilst additional evidence
was gathered. Is this workable given skepticism about risk sharing type arrangements? Is there a workable commercial model, given that payers normally
respond to greater uncertainty by seeking a lower price? During this session, adaptive licensing, coverage with evidence development, and other programs to Towse
deal with evidence uncertainty will be presented.
Moderator: Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
EARLIER ACCESS TO INNOVATION: REGULATORY AGENCY PERSPECTIVE
Speaker: Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicines Agency (EMA), London, UK
EARLIER ACCESS TO INNOVATION: INDUSTRY PERSPECTIVE
Speaker: Richard Bergström, MScPharm, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA),
Brussels, Belgium
EARLIER ACCESS TO INNOVATION: HTA AGENCY PERSPECTIVE
Speakers: Alric Rüther, MD, PhD, Head, Department of Health Care Quality, International Affairs, Institute for Quality and Efficiency in Health
Care (IQWiG), Cologne, Germany; Carole Longson, PhD, Director, Centre for Health Technology Evaluation and Executive Director, National
Institute for Health Care & Excellence (NICE), London, UK
Eichler
Bergström
Rüther
Longson
Coffee sponsored by Truven Health Analytics
Cookies sponsored by RTI Health Solutions
15:30-19:30 RESEARCH POSTER PRESENTATIONS - SESSION IV Room: Hall 2-3 (Ground Floor)
15:30-16:30 ISSUE PANELS - SESSION III
IP11: DECISION MAKING IN HEALTH CARE BASED ON ECONOMIC EVALUATION: REALITY OR JUST WISHFUL THINKING? EXPERIENCES FROM FOUR EUROPEAN
COUNTRIES Room: G102-103 (1st Floor)
Moderator: Andreas Uwe Gerber-Grote, MD, PhD, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Panelists: James P Raftery, PhD, Professor, NIHR Evaluation Trials and Studies Coordinating Centre (NETSCC), University of Southampton, Southampton, UK; Margreet
Franken, MSc, Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Emelie Heintz, PhD, Researcher, SBU,
Stockholm, Sweden
IP12: INTEGRATED CARE MODELS AS A POTENTIAL ROUTE FOR MARKET ACCESS OF INNOVATIVE MEDICAL DEVICES IN GERMANY? STAKEHOLDER
PERSPECTIVES ON THE CONCEPT Room: G104-105 (1st Floor)
Moderator: Stefan Walzer, PhD, MA, General Manager, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
Panelists: Daniel Droeschel, BSc, Health Economist, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany; Detlef Parow, MD, Head of Health Care
Management, DAK Gesundheit, Hamburg, Germany; Mathias Flume, PhD, Head of Health Care Management, Kassenaerztliche Vereinigung Westfalen-Lippe, Dortmund,
Germany
IP13: HOW DO THE VIEWS ON THE USE OF VALUE OF INFORMATION ANALYSES DIFFER BETWEEN POLICY MAKERS, INDUSTRY, AND RESEARCHERS?
Moderator: Manuela A. Joore, PhD, Researcher, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre,
Maastricht, The Netherlands
Panelists: Andrew Briggs, DPhil, MSc, William R. Lindsay Professor of Health Economics, Department of Health Economics & Health Technology Assessment, Institute
of Health & Wellbeing, University of Glasgow, Glasgow, UK; Meindert Boysen, MSc, HPPF, Director, Technology Appraisal Programme, Centre for Health Technology
Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK; Robin de Vries, PhD, Pharmacoeconomics Manager, Roche, Woerden, The Netherlands
USE OF REAL WORLD DATA ISSUES
IP14: REAL-WORLD COST-EFFECTIVENESS ANALYSIS: WHICH COMPARATOR HAS THE ULTIMATE X-FACTOR? Room: Elicium 1 (1st Floor)
Moderator: Carin A Uyl-De Groot, PhD, Director, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Panelists: Peter C. Huijgens, PhD MD, Director, The Comprehensive Cancer Centers The Netherlands (IKNL), Amsterdam, The Netherlands; Jolanda de Boer, MD,
Department Secretary, Scientific Advisory Committee, National Health Care Institute (ZIN), Diemen, The Netherlands; Elisabeth Maria van Rooijen, MD, Junior Researcher,
Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
IP15: HOW SHOULD A SOCIETAL PERSPECTIVE IN ECONOMIC EVALUATION BE IMPLEMENTED? Room: Elicium 2 (1st Floor)
Moderator: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Panelists: Werner Brouwer, PhD, Professor, Institute for Health Policy and Management (iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands; Karl Claxton,
PhD, Professor of Economics, Centre for Health Economics and Department of Economics, University of York, Heslington, York, UK; Ansgar Hebborn, PhD, Head, Global
Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland
16:45-17:45 WORKSHOPS - SESSION III
W13: ECONOMIC EVALUATION FOR LOW AND MIDDLE INCOME COUNTRIES: INTRODUCING THE BILL AND MELINDA GATES FOUNDATION GUIDELINES
Discussion Leaders: Paul Revill, MSc, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Mark J. Sculpher, MSc, PhD, Professor of
Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Thomas Wilkinson, BPharm, MSc, Adviser, Health Economics, NICE International,
National Institute for Health and Care Excellence (NICE), London, UK; Aurelio Mejía, MSc, Deputy Director of Health Technology Assessment, Instituto de Evaluación
Tecnológica en Salud (IETS), Bogota, Colombia
W14: THE ETHICAL AND LEGAL ISSUES AROUND THE USE OF SOCIAL MEDIA TO GET TO THE “REAL WORLD” Room: Elicium 1 (1st Floor)
Discussion Leaders: Andrew Cox, PhD, Senior Research Associate, Evidera, London, UK; H. Keri Yang, PhD, MPH, MS, Director, Global Health Outcomes, Merck & Co.,
Inc., West Point, PA, USA; Ruth Suter, MBA, Senior Director, Market Access and Patient Services, BioMarin Pharmaceuticals, San Rafael, CA, USA
W15: MIXED METHODS RESEARCH WITHIN CLINICAL TRIALS: OPERATIONAL CONSIDERATIONS Room: G106-107 (1st Floor)
Discussion Leaders: Alexia Marrel, BA, Associate Director, Health Economics and Outcomes Research, Mapi, Lyon, France; Frederico Calado, PharmD, Associate Director,
Global Patient Assess, Novartis, East Hanover, NJ, USA; Jean-Bernard Gruenberger, MPH, Global HEOR Director, GPA (Global Patient Access), Novartis, Basel, Switzerland;
Xavier Fournie, MD, Executive Vice President, Global Medical Affairs, Global Medical Affairs RWE, Mapi, Lyon, France
W16: DO CLASS EFFECTS EXIST ACROSS MULTIPLE MEDICAL THERAPEUTICS OR DO THEY REDUCE PATIENT CARE? Room: G104-105 (1st Floor)
Discussion Leaders: Heiner C. Bucher, MD, Professor, Internal Medicine, Basel Institute for Clinical Epidemiology & Biostatistics, Basel, Switzerland; Edward J Mills,
PhD, Associate Professor, Stanford University, Stanford, CA, USA; Christopher O’Regan, MSc, Head of Health Technology Assessment & Outcomes, Merck Sharp & Dohme
Limited, Hertfordshire, UK
W17: DYNAMIC SIMULATION MODELING TO EVALUATE COMPLEX SYSTEM INTERVENTIONS FOR HEALTH CARE DELIVERY RESEARCH – WHAT METHODS FOR
WHAT PROBLEMS? Room: Elicium 2 (1st Floor)
Discussion Leaders: Deborah A. Marshall, PhD, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health
Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada; Maarten J. IJzerman, PhD, Professor & Chair, Department
of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands; William
Padula, PhD, MSc, Postdoctoral Fellow, University of Chicago, Chicago, IL, USA; William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA
W18: DEVELOPMENT, VALIDATION, AND USE OF OBSERVER-REPORTED OUTCOMES IN CLINICAL TRIALS: CHALLENGES AND SOLUTIONS
Room: Auditorium (Ground Floor)
Discussion Leaders: Donald L. Patrick, PhD,MSPH, Professor, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle,
WA, USA; Rob Arbuckle, MSc, Director, Adelphi Values Ltd., Bollington, UK; Laurie Beth Burke, MPH, Founder, LORA Group, LLC, Royal Oak, MD, USA
17:45-19:30 EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV
Room: Hall 2-3 (Ground Floor)
Reception sponsored by Kantar Health
18:00-19:00 ISPOR FORUMS - SESSION II
F7: COST-EFFECTIVENESS ANALYSIS ALONGSIDE CLINICAL TRIALS - GOOD RESEARCH PRACTICES Room: Elicium 2 (1st Floor)
Moderator: Richard J. Willke, PhD, Vice President, Outcomes & Evidence Lead CV/Metabolic, Pain, Urology, Gender Health, Global Health & Value, Pfizer, Inc., New York,
NY, USA
Speakers: Henry Glick, PhD, Associate Professor of Medicine, University of Pennsylvania, Division of Internal Medicine, Philadelphia, PA, USA; Bengt Jönsson, PhD,
Professor of Health Economics, Stockholm School of Economics, Centre for Health Economics, Stockholm, Sweden; Shelby Reed, PhD, RPh, Associate Professor in Medicine,
Duke Clinical Research Institute, Durham, NC, USA
F8: HEALTH STATE UTILITY VALUES: MEASURING, MODELLING, AND MAPPING Room: Auditorium (Ground Floor)
Moderator: Sorrel Wolowacz, PhD, Head, European Health Economics, RTI Health Solutions, Manchester, UK
Speakers: Andrew Briggs, DPhil, MSc, Professor of Health Economics, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK; Allan J Wailoo, PhD,
Professor of Health Economics, ScHARR, University of Sheffield and Director, NICE Decision Support Unit, Sheffield, UK; Andrea Manca, PhD, MSc, Professor, Centre for
Health Economics, University of York, Heslington, York, UK
F9: VALUE IN HEALTH REGIONAL ISSUES: EXAMINING PRACTICAL ASPECTS OF MANUSCRIPTS SUBMISSIONS Room: G106-107 (1st Floor)
Moderator: Imre Boncz, MD, MSc, PhD, Habil, Co-Editor, Value in Health Regional Issues (CEEWAA) and Professor, Faculty of Health Sciences, University of Pécs, Pécs,
Hungary
Speakers: Mohamed Izham b. Mohamed Ibrahim, PhD, Co-Editor, Value in Health Regional Issues (CEEWAA) and, Professor of Social & Administrative Pharmacy,
College of Pharmacy, Qatar University, Doha, Qatar; Dan Greenberg, PhD, Co-Editor-in-Chief, Value in Health Regional Issues (CEEWAA) and Associate Professor &
Chairman, Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Federico Augustovski, MD, MSc, PhD, Co-Editor-in-Chief,
Value in Health Regional Issues (Latin America), Director, Economic Evaluations & HTA Department; Institute for Clinical Effectiveness and Health Policy (IECS), Professor
of Public Health, University of Buenos Aires, Buenos Aires, Argentina; Bong-Min Yang, PhD, Co-Editor-in-Chief, Value in Health Regional Issues (Asia) and Professor of
Economics, School of Public Health and Executive Director, Institute of Health and Environment, Seoul National University, Seoul, South Korea
F10: THE BENEFITS OF INNOVATIVE MEDICINES IN CENTRAL AND EASTERN EUROPEAN (CEE) COUNTRIES Room: G104-105 (1st Floor)
Moderator: Guenka Petrova, DSci, President, ISPOR Bulgaria Chapter and Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
Speakers: Dominik Tomek, PharmD, PhD, MPH, Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic; Liubov Krasnova, PhD,
Executive Director, The Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia; Joanna Lis, PhD, President, ISPOR Poland Chapter, Adjunct,
Faculty of Pharmacy, Department of Pharmacoeconomics, Medical University of Warsaw, and Market Access Director, Sanofi, Warsaw, Poland; Viacheslav Tolubaiev,
PharmD, PhD, Clinical Research Associate, Local Study Leader, AstraZeneca Ukraine, Kyiv, Ukraine; Zoran Sterjev, PharmD, PhD, Vice-Dean, Faculty of Pharmacy, UKIMSkopje, Skopje, Macedonia
F11: THE POLICY CHALLENGES OF RARE DISEASES IN THE CENTRAL AND EASTERN EUROPEAN (CEE) REGION Room: Elicium 1 (1st Floor)
Moderator: Malwina Holownia, MPharm, Director of Economics, The Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
Speakers: Elena Verich, MSc, Regulatory Affairs Manager & Products Patrimony Manager, Quality Officer, Sanofi, Minsk, Belarus; Jan Hambalek, MSc, Head of
Pharmacoeconomic Department, State Institute of Drug Control, Prague, Czech Republic; Maria Avksentyeva, MD, PhD, ScD, Deputy Director, HTA Centre at RANEPA
(Russian Academy of National Economy and Public Administration), Moscow, Russia; Karina Jahnz-Rozyk, MD, Professor & Head of Department of Immunology & Clinical
Allergology, Military Institute of Medicine, Warsaw, Poland; Tarik Catic, MScPharm, President, ISPOR Bosnia and Herzegovina Chapter and Health Economics Consultant,
Sarajevo, Bosnia and Herzegovina
F12: NEW DEVELOPMENTS IN HEALTH POLICY IN ITALY Room: G102-103 (1st Floor)
Moderators: Lorenzo Mantovani, DSc, President, ISPOR Italy-Milan Chapter and Senior Researcher, Department of Clinical Medicine and Surgery, Federico II University
of Naples, Naples, Italy; Francesco Saverio Mennini, MSc, President, ISPOR Italy- Rome Chapter, Professor of Health Economics and Research Director, CEIS Economic
Evaluation and HTA (EEHTA), University Tor Vergata Roma, Rome, Italy
Speakers: Patrizia Berto, PharmD, MBA, Senior Vice-President, Business Development & Marketing, LA-SER Group Italy, Milan, Italy; Filippo Buccella, MD, President,
Parent Project – Onlus, Chairman, EUPATI National Liaison Team Italy, Rome, Italy; Paolo Angelo Cortesi, PhD, Research fellow, Research Centre on Public Health (CESP) University of Milano-Bicocca, Monza, Italy; Matteo Ruggeri, MSc, PhD, Project Leader & Lecturer, ALTEMS, Università Cattolica del Sacro Cuore (UCSC), Graduate School in
Health Economics and Management, Rome, Italy; Paolo Daniele Siviero, MSc, Director, Research Center, Italian Pharmaceutical Agency (AIFA) Drug Assessment, Rome, Italy
18:30-19:30 POSTER AUTHOR DISCUSSION HOUR - SESSION IV Room: Hall 2-3 (Ground Floor)
20:00-23:30 ISPOR SOCIAL EVENT Separate Registration Required
Network with colleagues and discover a world of science and technology at the NEMO Science Center!
Approximately 15 minutes from the RAI to the NEMO Science Center
To register: Please see ISPOR Registration, onsite registration is subject to availability
Social Event registrants: Please see Key Information for further information
You can engage in ISPOR activities in the Central & Eastern
European (CEE) region via the ISPOR CEE Network! For details:
http://www.ispor.org/ceenetwork/index.asp or scan this QR code
program & schedule of events: wednesday, 12 November
Wednesday, 12 November
7:30-8:30
EDUCATIONAL SYMPOSIUM Room: G102-103 (1st Floor)
Durable Long-Term Survival IN CANCER PATIENTS – DEFINING NOVEL VALUE METRICS AND METHODOLOGIES
IN AN ERA OF IMMUNO-ONCOLOGY MEDICINES
Sponsored by Bristol-Myers Squibb
8:45-14:45
RESEARCH POSTER PRESENTATIONS - SESSION V Room: Hall 2-3 (Ground Floor)
8:45-9:45
WORKSHOPS - SESSION IV
W19: USING MULTI-CRITERIA DECISION ANALYSIS TO EVALUATE THE POTENTIAL OF BIOSIMILARS TO LOWER COSTS IN ONCOLOGY Room: G104-105
(1st Floor)
Discussion Leaders: Dennis W Raisch, PhD, MS, RPh, Professor & Chair, PEPPOR Graduate Program, University of New Mexico College of Pharmacy, Albuquerque,
NM, USA; Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services
Research, MIRA Institute for Biomedical Technology & Technical Medicine, University of Twente, Enschede, The Netherlands; Charles Bennett, MD, PhD, MPP, CoEE
Endowed Chair in Medication Safety and Efficacy & Frank P. and Josie M. Fletcher Professor of Pharmacy, University of South Carolina, Columbia, SC, USA; Martin van der
Graaff, PhD, Secretary, Pharmacoeconomics Advisory Committee, National Health Care Institute (ZIN), Diemen, The Netherlands
W20: THE NUMBER TO TREAT PRINCIPLE AS ALTERNATIVE METHOD TO DETERMINE EFFECTIVENESS AND EFFICIENCY OF MEDICINAL PRODUCTS
Discussion Leaders: Marja H Pronk, MD, Managing Director, Policy, Pronk & Van Woudenberg Health Care Consultancy, Woerden, The Netherlands; Mark J. C. Nuijten,
PhD, MD, MBA, Founder, Ars Accessus Medica, Jisp, The Netherlands; Carla Schoonderbeek, Master of Law, Partner, Hoyng Monegier LLM, Amsterdam, The Netherlands
W21: PATIENT ENGAGEMENT IN OUTCOMES RESEARCH: CURRENT STATUS, QUESTIONS, BELIEFS, AND FUTURE PERSPECTIVES Room: Auditorium
(Ground Floor)
Discussion Leaders: Todd Berner, MD, Executive Medical Director, Urology, Astellas Scientific and Medical Affairs, Inc., Northbrook, IL, USA; Asha Hareendran, PhD, MA,
Senior Research Scientist, Evidera, London, UK; Rachel Harrington, BA, Senior Regulatory Submissions Manager, Astellas Pharma Global Development, Northbrook, IL, USA;
Amie M. Scott, MPH, Research Project Manager, Memorial Sloan Kettering Cancer Center, New York, NY, USA
W22: VALUE OF INFORMATION – WHAT IS ITS VALUE FROM A MANUFACTURER’S PERSPECTIVE? Room: G106-107 (1st Floor)
Discussion Leaders: Aline Gauthier, MSc, Director, Health Economics and Outcomes Research, Amaris, London, UK; Kyle Dunton, MSc, Research Analyst, Health
Economics and Outcomes Research, Amaris, London, UK; Stuart Carroll, MSc, MBA, Senior Health Economist & Market Access Specialist, Imperial College Business School,
Imperial College, London, UK
W23: THE FIRST STEP TO IMPROVE PATIENTS’ HEALTH CARE IS TO KNOW WHAT TO IMPROVE: DEMONSTRATING THE USE OF ‘GROUP CONCEPT MAPPING’ AS A
NOVEL WAY TO DEVELOP A PATIENT-CENTERED DISEASE MODEL AND ENRICH CONTENT VALIDITY Room: Emerald Room (1st Floor)
Discussion Leaders: Thomas G. Willgoss, PhD, Project Manager, Clinical Outcomes Assessment, Abacus International, Manchester, UK; Louise Humphrey, MSc, Director
& Head, Clinical Outcomes Assessment, Abacus International, Manchester, UK; Tara Symonds, PhD, Head of PRO Centre of Excellence, Global Market Access, Primary Care
Business Unit, Pfizer, Kent, UK; Joseph C Cappelleri, PhD, MPH, Senior Director, Pfizer Inc, Groton, CT, USA
9:45-10:00
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V Room: Hall 2-3 (Ground Floor)
Coffee sponsored by RTI Health Solutions
10:00-11:00 ISSUE PANELS - SESSION IV
IP16: MULTICRITERIA FOR REAL LIFE DECISION MAKING? PERSPECTIVES AND EXPERIENCE FROM THE FIELD Room: G106-107 (1st Floor)
Moderator: Mireille Goetghebeur, PhD, MEng, Global Scientist, LASER Analytica, Montreal, QC, Canada
Panelists: François Meyer, MD, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Paris, France; Sarah Garner, PhD, BPharm, Associate
Director, Research and Development, National Institute for Health and Care Excellence (NICE), London, UK; Michele Tringali, MD, Deputy Officer, HTA Program, Direzione
Generale Salute, Regione Lombardia, Milan, Italy
IP17: CAN WE ALLEVIATE NEGATIVE CONSEQUENCES OF EXTERNAL PHARMACEUTICAL PRICE REFERENCING IN MIDDLE EAST COUNTRIES?
Moderator: Panos Kanavos, PhD, Reader in International Health Policy, Medical Technology Research Group, London School of Economics and Political Science, London, UK
Panelist: Ola Ghaleb Al Ahdab, Pharm, PGD, PhD, Pharmaceutical Advisor, Drug Department, Ministry of Health, Abu Dhabi, United Arab Emirates; Mahmoud
Elmahdawy, PharmD, Director, Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Egyptian Ministry of Health, Cairo, Egypt; Kasem
Akhras, PharmD, Head of Market Access MENA Region, Pharma Service, Novartis, Dubai, United Arab Emirates
program & schedule of events: wednesday, 12 November continued
IP18: IS THERE ROOM FOR MULTI-CRITERIA DECISION MAKING IN CENTRAL & EASTERN EUROPEAN COUNTRIES WITH SEVERE FINANCIAL CONSTRAINTS?
Moderator: Vladimir Zah, Health Economist and Founder, ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro
Panelists: Katarzyna Kolasa, PhD, Senior Research Fellow, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland; Zoltan Kalo, MD, MSc,
PhD, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary; Pavel Vorobiev, MD, PhD,
President, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
IP19: EARLY ACCESS TO THERAPIES THROUGH ADAPTIVE LICENSING: HOW DO YOU MAKE IT WORK FOR ALL KEY STAKEHOLDERS? Room: Auditorium
(Ground Floor)
Moderator: Francois Lucas, PhD, Principal, Pope Woodhead and Associates, St. Ives, UK
Panelists: Omar Ali, DipClinPharm, MRPharmS, ACPP, Formulary Development Pharmacist, Surrey & Sussex NHS Trust, Redhill, UK; Bruno Flamion, MD, PhD,
Pharmacological and Medical Expert, Federal Agency for Medicines and Health Products, Brussels, Belgium; Sanda Rocak, PhD, Global Value Strategy Lead, Global Market
Access, Shire, Eysins, Switzerland
PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES
IP20: CAN MIXED METHODS RESEARCH BE THE SOLUTION TO THE CHALLENGES OF PATIENT-CENTERED OUTCOME RESEARCH IN THE CONTEXT OF RARE
DISEASES? Room: Emerald Room (1st Floor)
Moderator: Antoine Regnault, PhD, Research Director, HEOR & Strategic Market Access, Mapi, Lyon, France
Panelists: Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France; Francois Houyez, MSc, Treatment Information and Access Director
& Health Policy Advisor, European Organisation for Rare Diseases (Eurordis), Paris, France; Tara Symonds, PhD, Head of PRO Centre of Excellence, Global Market Access,
Global Health and Value, Pfizer Ltd., Tadworth, UK
11:15-12:30 WELCOME & THIRD PLENARY SESSION Room: Auditorium (Ground Floor)
WELCOME
Towse
THIRD PLENARY SESSION: HEALTH CARE EVIDENCE: CAN WE GET TO THE ‘REAL WORLD’?
Pressure for “real world” evidence from many health technology assessment (HTA) bodies and payers as well as from the European Medicines Agency (EMA)
for post-authorisation efficacy studies has run up against several obstacles: can we generate “real world” observational data? Can we analyse it in a way
that addresses bias and confounding? How are health care databases used in outcomes research? Can we make experimental studies more “real world”?
This session will address a core ISPOR area that has experienced an impressive renaissance.
Moderator: Finn Børlum Kristensen, MD, PhD, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and
Kristensen
Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
THE NORDIC HEALTHCARE REGISTRIES – REAL IMPROVEMENT TO OUTCOMES RESEARCH?
Speaker: Lars Pedersen, MSc, PhD, Professor, Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
PILLS, PEOPLE, AND PREFERENCES: EVALUATING REAL-LIFE PRACTICE IN PRAGMATIC TRIALS
Speaker: Hilary Pinnock, MB ChB, MD, MRCGP, Reader, Asthma UK Centre for Applied Research, Centre for Population Health Sciences,
University of Edinburgh and General Practitioner, Whitstable Medical Practice, Whitstable, Kent, UK
Pedersen
Pinnock
STRATEGIES TO REDUCE BIAS AND INCREASE MEANINGFULNESS OF FINDINGS FROM REAL WORLD DATA
Speaker: Sebastian Schneeweiss, MD, ScD, Professor of Medicine and Epidemiology, Harvard Medical School, Boston, MA, USA
Schneeweiss
12:30-12:45 ISPOR 17th ANNUAL EUROPEAN CONGRESS RESEARCH PRESENTATION AWARDS
Moderator: Adrian Towse, MA, MPhil, 2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
ISPOR BEST PODIUM PRESENTATIONS
Presented by: Kostas Athanasakis, PhD, Research Fellow, National School of Public Health and President of the Hellenic Association of
Pharmacoeconomics, Athens, Greece
Towse
ISPOR BEST POSTER PRESENTATIONS
Presented by: Phil McEwan, PhD, Director, Health Economics and Outcomes Research Ltd., Monmouth, Wales, UK
Athanasakis McEwan
12:45-13:45
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V Room: Hall 2-3 (Ground Floor)
12:45-13:45 POSTER AUTHOR DISCUSSION HOUR - SESSION V Room: Hall 2-3 (Ground Floor)
program & schedule of events: wednesday, 12 November continued
13:45-14:45 WORKSHOPS - SESSION V
W24: A TALE OF TWO AUDIENCES: OPTIMISING YIELD FROM EARLY ADVICE CONSULTATION WITH HTA AND REGULATORY ORGANISATIONS
Room: Emerald Room (1st Floor)
Discussion Leaders: Cyrus A. Chowdhury, MS, Chief Executive Officer and Managing Director, CBPartners, New York, NY, USA; Matthieu R. Cuche, PharmD, MBA,
Director HCE & Reimbursement, Covidien AG, Zürich, Switzerland; Marije van Weelden, MD, MBA, MSc, Director, Market Access & Pricing Europe, Ferring, Saint-Prex,
Switzerland; Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA
W25: HOW CAN PATIENT ONLINE COMMUNITIES INFORM INDUSTRY ABOUT BARRIERS TO MEDICATION ACCEPTANCE AND UNMET NEEDS? LESSONS LEARNED
FROM A FRENCH MULTI-DISEASES STUDY USING A PATIENT ONLINE COMMUNITY Room: G102-103 (1st Floor)
Discussion Leaders: H. Gilet, MSc, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France; Michael Chekroun, MSc, Chief Executive Officer,
carenity.com, Paris, France; Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France
W26: HOW AN EARLY NETWORK META-ANALYSIS (NMA) HELPS INFORM CLINICAL TRIAL DESIGN AND TECHNOLOGY APPRAISAL (TA) SUBMISSIONS?
Discussion Leaders: Yingxin Xu, PharmD, PhD, Research Scientist, Meta Research, Evidera, Lexington, MA, USA; Kyle Fahrbach, PhD, Senior Biostatistician, Meta
Research, Evidera, Lexington, MA, USA; Floortje E van Nooten, MSc, Associate Director, HEOR, Astellas, Leiden, The Netherlands; Grace Jennings, PhD, Technical Adviser,
National Institute for Health and Care Excellence (NICE), Manchester, UK
W27: CHANGING PERSPECTIVES, CHANGING VALUES: MOVING BEYOND COST-EFFECTIVENESS ANALYSIS Room: Auditorium (Ground Floor)
Discussion Leaders: Josephine A. Mauskopf, PhD, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA; Baudouin Standaert,
MD, MSc, Head, Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium; Stephanie R. Earnshaw, PhD, Vice President, Health Economics US, RTI Health Solutions,
Research Triangle Park, NC, USA; Mark Connolly, PhD, Managing Director, Global Market Access Solutions, Switzerland and United States and Guest Researcher, University
of Groningen, Groningen, The Netherlands
W28: PATIENT-REPORTED OUTCOMES IN A PRODUCT’S LIFECYCLE: THE IDEAL AND THE REALISTIC STRATEGIES Room: G106-107 (1st Floor)
Discussion Leaders: Brooke Witherspoon, BA, Associate Director, Endpoint Outcomes, Boston, MA, USA; Somali Misra Burgess, PhD, Chief Executive Officer & Research
Director, Strategic Outcomes Services, Mission Viejo, AZ, USA; Kristina Fitzgerald, MPH, Global Head of PRO for Immunology, Infectious Disease & Ophthalmology,
Genentech Inc., South San Francisco, CA, USA
Coffee sponsored by RTI Health Solutions
15:00-16:00 WORKSHOPS - SESSION VI
W29: SUPPORTING DECISION MAKING WITH MCDA: RECOMMENDATIONS FOR DEALING WITH UNCERTAINTY Room: Emerald Room (1st Floor)
Discussion Leaders: Maarten J. IJzerman, PhD, Professor of Health Technology & Services Research, Health Technology & Services Research, MIRA Institute for Biomedical
Technology & Technical Medicine and University of Twente, Enschede, The Netherlands; Kevin Marsh, PhD, Director, Modelling and Simulation and Senior Research Scientist,
Health Economics, Evidera, London, UK; Henk Broekhuizen, MSc, PhD Student, Health Technology & Services Research, University of Twente, Enschede, The Netherlands;
Karin Groothuis-Oudshoorn, PhD, Assistant Professor, Health Technology & Services Research, University of Twente, Enschede, The Netherlands
W30: AS REAL AS IT GETS: CHALLENGES IN SETTING UP PATIENT REGISTRIES FOR THE COLLECTION OF REAL-WORLD DATA ON BEHALF OF POLICY MAKING
Discussion Leaders: Margreet Franken, MSc, Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Hans
Westgeest, MD, Medical Oncologist, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; Ruud Simons, MBA, MBI, Senior
Project Manager, National IT Institute for Healthcare in The Netherlands (NICTIZ), The Hague, The Netherlands; Naomi van der Linden, MSc, Researcher, Institute for
Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
W31: CAN WE MAKE INDIRECT COMPARISONS AND NETWORK META-ANALYSIS USEFUL FOR CLINICIANS AND PATIENTS OR IS IT JUST FOR HEALTH
TECHNOLOGY ASSESSMENTS? Room: G104-105 (1st Floor)
Discussion Leaders: Edward J Mills, PhD, Associate Professor, Stanford University, Stanford, CA, USA; Heiner C. Bucher, MD, Professor, Internal Medicine, Basel Institute
for Clinical Epidemiology & Biostatistics, Basel, Switzerland; Carl Baxter, MChem, PhD, EBM & OR Manager, MSD Ltd., Hoddesdon, UK
W32: EVALUATION OF RISK-SHARING AGREEMENTS – A REAL-OPTION APPROACH Room: G106-107 (1st Floor)
Discussion Leaders: Olivier Ethgen, MSc, PhD, Adjunct Professor Health Economics, University of Liege, Liege, Belgium; Augustin Terlinden, Msc, Health Economist,
Health Economics, Navigha, Tervuren, Belgium
W33: INTEGRATING THE PATIENT PERSPECTIVE IN THE ASSESSMENT OF BENEFITS AND RISKS OF MEDICINES Room: Auditorium (Ground Floor)
Discussion Leaders: Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France; Carla Dias Barbosa, MSc, Senior Research Manager,
HEOR & Strategic Market Access, Mapi, Lyon, France; Kimberley Hockley, MPH, Research Postgraduate and Team Leader for Patients and Public Involvement Working
Group of the IMI-PROTECT Work Package Five, School of Public Health, Imperial College London, London, UK; Donald L. Patrick, PhD, MSPH, Professor, Seattle Quality of
Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

PROGRAM & SCHEDULE OF EVENTS ISPOR 17th Annual European Congress 8-12 NOVEMbER 2014

Transcription

Similar documents

international conference places on the edge creating a sense of

Ministry of Education and Sports -African Development Bank- CIAT

академ программы англ

10 MEETING OF LIFE SCIENCE DOCTORAL STUDENTS ... , 2014

Here - Society of International Economic Law

Overcoming Implementing Increasing Cooperating

CSE506 PhD Section Overview Nima Honarmand

Hospital-Wide Awards $2,500 Team Awards (2) Poster #

Change in Program Plan – Graduate Studies

VEOIBD 2014 Very Early Onset Inflammatory Bowel Disease Symposium Save the Date:

PROGRAM &amp; SCHEDULE OF EVENTS ISPOR 17th Annual European Congress 8-12 NOVEMbER 2014

Transcription

Similar documents

PROGRAM & SCHEDULE OF EVENTS ISPOR 17th Annual European Congress 8-12 NOVEMbER 2014